EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis-Reference-Cited by-同舟云学术

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Published:2016-05-25 Issue:18 Volume:22 Page:4585-4593
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Gainor Justin F.,Shaw Alice T.,Sequist Lecia V.,Fu Xiujun,Azzoli Christopher G.,Piotrowska Zofia,Huynh Tiffany G.,Zhao Ling,Fulton Linnea,Schultz Katherine R.,Howe Emily,Farago Anna F.,Sullivan Ryan J.,Stone James R.,Digumarthy Subba,Moran Teresa,Hata Aaron N.,Yagi Yukako,Yeap Beow Y.,Engelman Jeffrey A.,Mino-Kenudson Mari

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 990 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Orchestrated metal-coordinated carrier-free celastrol hydrogel intensifies T cell activation and regulates response to immune checkpoint blockade for synergistic chemo-immunotherapy;Biomaterials;2025-01

2. Reduced frequency and severity of radiation esophagitis without marginal failure risk by contralateral esophagus sparing IMRT in stage III non-small cell lung cancer patients undergoing definitive concurrent chemoradiotherapy;Radiotherapy and Oncology;2024-10

3. Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors;Cancer Immunology, Immunotherapy;2024-09-13

4. Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non–small cell lung cancer;Journal of Managed Care & Specialty Pharmacy;2024-09-11

5. Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer;CLIN LUNG CANCER;2024